Aging may to some extent explain the reasons why the prognosis was worse for older patients but not for younger patients. 6, 7 It was reported that this age disparity in breast cancer survival can be explained by pathologic factors such as hormone receptor status or treatment. [8] [9] [10] [11] However, the disparity remains even under control of the clinicopathologic features, treatments, or comorbid conditions. [12] [13] [14] Therefore, the reasons for the survival disparity of breast cancer need exploration, particularly for the young patients. Clarifying this issue would help provide opportunities for novel moleculartargeted therapies and improve the prognosis. We noticed that a series of studies have found certain intrinsic molecular feature changes which were related to age at diagnosis of invasive breast cancer. 15 For example, GATA3 mutations in breast tumors occurred more frequently in young patients 16 ; significant upregulation of miRNA-148b
was shown in young breast cancer patients 17 ; molecular subtype that was determined by gene expression profiling presented age-associated patterns, in which young patients were more likely to have basal-like subtype 15 ; age-related DNA methylations were observed in normal breast tissue as well as invasive breast tumors. 18, 19 Furthermore, some of these molecular features have been found to be associated with breast cancer survival. [20] [21] [22] Therefore, these molecular features may have effects on the associations between age and breast cancer prognosis.
In this study, we investigated the impacts of the molecular features in young vs elderly breast cancer patients, such as gene and miRNA expression profiles, somatic mutations, and DNA methylation profiling, on survival disparities by age at diagnosis through the breast cancer clinical and molecular data from the Cancer Genome Atlas (TCGA).
| METHODS

| Patients
We applied the R/Bioconductor TCGAbiolinks package 23 (http://bioconductor.org/packages/TCGAbiolinks/) to download all available breast cancer data from Genomic Data Commons (GDC) data portal (https://portal.gdc.cancer. gov/) on May 15, 2017. Meanwhile, molecular data including gene expression, somatic mutations, miRNA expression, and DNA methylation profiling were obtained. Clinical data included survival information, age at diagnosis, race, tumor size, lymph node status, histological type, clinical stage, and statuses of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These hormone receptors were identified by immunohistochemistry. For HER2 status classification, if immunohistochemistry result was equivocal, fluorescent in situ hybridization was used. The endpoint for this study was recurrence-free survival (RFS), which was defined as the time from diagnosis to the date of recurrence or last followup. Patients with stage IV were excluded because the tumor relapse could not be assessed adequately. A total of 1097 breast carcinoma patients were obtained from TCGA dataset and 41 of them, who were male or diagnosed with stage IV, were excluded. Finally, 1056 eligible breast cancer patients were included in the analysis; 880 patients were successfully followed up; 86 patients experienced breast cancer relapse during the follow-up period.
| Molecular variables
Gene and miRNA expressions were assessed with RNA sequencing data. Breast cancer PAM50 molecular subtype was identified using the genefu R/Bioconductor package. Risk score for prognosis was calculated based on 7 miRNAs and 30 mRNA genes. 24 Patients were stratified into low-or highrisk groups by median cut 0.033. A total of 729 patients were assessed for the risk stratification. For PAM50 subtypes, 1054 patients were typed by gene expression analysis.
The tumor somatic mutations examined by whole-exome sequencing from 986 patients were analyzed. Only genes with potential driver mutations in more than 5% of breast cancer patients were included. 25 Finally, 6 mutated genes were identified, including TP53, PIK3CA, MLL3, CDH1, GATA3, and MAP3K1. DNA methylation profiling on Illumina 450K and 27K platforms was downloaded. We applied Horvath' method to predict tumor DNA methylation (DNAm) age, 19 which is currently the most robust predictor of chronological age. 26 Briefly, 353 dinucleotide markers were identified as epigenetic clock CpGs from 21,369 CpG probes on the Illumina 27K and 450K platforms with a penalized regression model. Based on the 353 CpGs, DNAm age was estimated as follows.
The mathematical details and software tutorials for DNAm age calculation can be found in the additional files of Horvath. 19 An online age calculator (https://dnamage.genetics.
ucla.edu) is available, by which the DNAm age for the breast cancerous tissues were obtained. Age acceleration (AgeAccel) was calculated by DNA methylation age minus chronological age and analyzed as a binary variable by the cutoff zero.
| Statistical analysis
According to the result of the association between age and breast cancer recurrence by cubic restricted splines (as shown in Figure 1 ), under 40 years old was regarded as "young patients"; 60 years and older were defined as "elderly patients"; others were classified as "middle-aged The Kaplan-Meier curve and the log-rank test were used for the comparison of recurrence-free survival by age group. Only the patients with full tumor recurrence information were analyzed. To explore the age nonlinear effect on RFS of breast cancer, the age was modeled as a continuous variable and fitted in a Cox proportional hazard model using cubic restricted splines with knots at the 5th, 35th, 65th, and 95th percentiles of age. The relative contribution of each covariable to age disparities in survival was estimated by Cox proportional hazard models with or without the variable of interest. The covariables in baseline model contained age group, race, tumor size, and node status. The influence of molecular covariable on age survival disparities was tested stepwise by adding PAM50 subtype, risk stratification, DNAm age, and 6 gene mutations to the baseline model for adjustment. Hazard ratio (HR) and 95% confidence interval (95%CI) were estimated. The contribution of the covariables was assessed by the equation of (HR − − HR + )/HR 0 *100, in which HR 0 is the HR from the baseline model, HR -is the HR from the model without the covariable of interest, and HR + is the HR from the model with the covariable of interest. 27 Concordance index (c-index) was applied to evaluate model discrimination. A multinomial propensity score weighting analysis for 3 age groups of patients using R/twang (version 1.5) package (https://CRAN.R-project.org/package=twang) was performed to probed the age-related difference in breast cancer recurrence, in which race, hormone status, tumor size, node status, basal-like subtype, DNAm age, 6 gene somatic mutations, and risk score stratification were balanced. P < .05 was considered to be statistically significant. Statistical analyses were performed using the R-3.3.3 software.
| RESULTS
| Clinicopathological characteristics and the association with age at diagnosis
The mean age of the included 1056 female breast cancer patients was 58.4 years old. Less than 20% were African Americans. Most of the patients were infiltrating ductal carcinoma (71.3%), clinical stage II (58.6%), and ≤2 cm of tumor size (84.3%). More patients were ER or PR positive and HER2 negative. The distributions of these clinicopathological characteristics by age group were shown in Table 1 . Young patients were more likely to have infiltrating ductal carcinoma, and be node positive, ER negative, and PR negative. There was a trend of higher pathologic stage, larger tumor size, and more black people in young patients, but no statistical differences were found. 
| Associations between molecular characteristics and the age at diagnosis
| Associations of molecular characteristics with breast cancer recurrence
The associations between the molecular characteristics and recurrence-free survival for breast cancer were shown in Table 3 . Younger DNAm age or low DNAm age acceleration, PAM50 basal-like subtype, and high RNA risk were significantly associated with an increased risk of tumor recurrence. No significant association between gene mutations and breast cancer relapse was found.
| Age effect on breast cancer recurrence and the impact of molecular features
When age was modeled as a continuous variable and fitted in the multivariable Cox proportional hazard model using cubic restricted splines to estimate age nonlinear effect, an obvious nonlinear association between age and RFS was shown (P = .012, Figure 1 ). elderly breast cancer patients had a shorter time to relapse than the middle-aged patients (Figure 2 , P < .001).
We then explored the contribution of molecular features to age-related disparities in breast cancer recurrence (Table 4 ). In the univariate model, the young patients had a 2.96-fold increase in the risk of breast cancer recurrence compared with the middle-aged patients (HR [95% CI]: 2.96 [1.54, 5.67]). After adjusted by race, tumor size, and node status, the HR was slightly decreased (Model 2 in Table 4 ). We further adjusted stepwise, the PAM50 subtype (Model 3), risk stratification (Model 4), DNAm age (Model 5), and gene mutations (GATA3, PIK3CA, MLL3, CDH1, TP53, and MAP3K1) (Model 6-11), it turned out that the strength of the association between breast cancer recurrence and young patients over middle-aged patients was gradually weakened. In Model 5 to model 11, the association was not statistically significant and all the molecular features overall decreased 33.5% ([2.81-1.87]/2.81) of the recurrence risk among the young patients compared with the middle-aged patients. For the elderly patients, however, the poor prognosis persisted after the adjustment of these molecular characteristics.
Finally, we performed a propensity score analysis, balancing race, tumor size, node status, PAM50 molecular subtype, 
| DISCUSSION
In this study, we confirmed that young and old age at diagnosis were associated with an unfavorable clinical outcome in breast cancer compared with the middle-aged patients, which was in line with most of the previous studies. 5, 11, 28 However, a few of previous studies did not find the nonlinear association between age and survival prognosis. 29, 30 Meanwhile, several studies proposed that age was not an independent prognostic factor for breast cancer. 31, 32 We noticed that these previous studies applied various cutoff values of age, such as that young age was defined as under the ages of 30, 35, 40, 45, or 50, 33 which might contribute to the inconsistent results. We firstly applied cubic restricted splines to accordingly define "young patients," "middleaged patients," and "elderly patients," which was consistent with Jianfei's definition determined by X-tile program. 33 It may be understandable and reasonable that elderly breast cancer patients had a worse prognosis than middleaged patients due to the impaired capacity with aging or undertreatment. 7, 10, 34, 35 As for the worse prognosis of young patients, previous studies have attributed it to tumor invasiveness, hormone status, tumor subtype, and treatment. 8, [36] [37] [38] [39] We also similarly observed that these tumor characteristics contributed to the poor prognosis for young patients to some extent. Moreover, this study showed that the adjustments of the molecular features substantially decreased the strength of the association between young age and survival prognosis (33.5%), suggesting that the molecular characteristics also likely played roles for the poor prognosis of young patients. The molecular characteristics with significant impacts found in this study included PAM50 subtype, DNAm age, and GATA3 mutations. It was shown that PAM50 subtype decreased the strength of the association between age and prognosis of breast cancer, which was in line with the results from previous studies using the molecular subtype determined by 46 We found that younger DNAm age decreased the strength of the association between chronological age and prognosis of breast cancer. It can be explained partly by the association that younger tumor DNAm age had a poor prognosis, which has also been reported in several other cancers. 26 Younger DNAm age was associated with the potential to promote malignant transformation and propagation 19 resulting in the increase in breast cancer relapse; it was also related to higher frequencies of genetic mutations which increased the invasiveness for young breast cancer patients. 19, 26 We did not find the impact of DNAm age in the elderly, which may be explained to some extent by that the association between DNAm age and chronological age dramatically declined with increased age. 47 We further found that GATA3 mutations might play a role in the poor prognosis for young patients. A total of 140 somatic mutations in GATA3 were detected in 13.7% of 986 patients in the TCGA database (updated May 15, 2017) . Among them, more than two-thirds (67.8%) were frame shift mutations which resulted in proteins with extended C-terminus and induced peptidyl-tyrosine modification and cancer progression. 48 It was also reported that mutations of GATA3 in breast cancer cells were related to reduced DNA binding ability and increased cell proliferation, resulting in endocrine resistance. 49, 50 We found that the old patients had much less frame shift mutations in GATA3 than young patients, which may be the reason that GATA3 mutations had no effects on the associations between age and prognosis of breast cancer.
Models n/event
Hazards ratio (95% CI) We conducted a four-step approach proposed by Baron and Kenny 51 to test the potential mediation effects of the molecular features on the association between age and prognosis. First, age at diagnosis affected molecular features in logistic regression; second, the molecular features were associated with survival prognosis in Cox's regression model; third, associations between age and the prognosis were examined in Cox's regression model with and without adjustment of the molecular features (potential intermediate variables); finally, the significances and changes of hazard ratios derived from the models with or without the adjustments were taken as the evidence of mediation. It should be noted that this method still only statistically proved the mediation effects and the causal interpretation remains to be explored, particularly by biological experiments. There were also some other potential limitations in this study. First, breast cancer-specific fatality was not included as the outcome due to the lack of death causes in TCGA database. However, recurrence-free survival may more accurately reflect breast cancer-specific survival. Second, we did not have the information about potential confounders such as sociodemographic and therapy, but this missing information may not change the mediating effects of the molecular features on age-related prognosis because it was reported that age was an independent prognostic factor regardless of sociodemographic and therapy. 5, 12 Third, the small sample size may reduce the statistical power, which was probably the reason for the results that there were nonsignificant effects of RNA risk score and the mutations of other genes (TP53, PIK3CA, MLL3, CDH1, MAP3K1) on the association between age and the prognosis of breast cancer.
In conclusion, we demonstrated that tumor molecular features could contribute to the known poor prognosis for young breast cancer patients (accounted for 33.5% of disparities in poor prognosis) but not for the elderly. These results suggested that the intrinsic molecular features likely played a fundamental role in the poor prognosis for young patients. The molecular-targeted therapies among young patients can promisingly improve survival prognosis.
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